Dyne Therapeutics, Inc. financial data

Symbol
DYN on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 02 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1787% % -8.1%
Debt-to-equity 21% % 143%
Return On Equity -61% % -25%
Return On Assets -51% % -13%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142,824,687 shares 40%
Common Stock, Shares, Outstanding 164,950,540 shares 61%
Entity Public Float $948,000,000 USD -68%
Common Stock, Value, Issued $16,000 USD 60%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $398,333,000 USD 42%
General and Administrative Expense $69,851,000 USD 12%
Operating Income (Loss) $468,184,000 USD -36%
Net Income (Loss) Attributable to Parent $446,214,000 USD -41%
Earnings Per Share, Basic -3.47 USD/shares -3%
Earnings Per Share, Diluted -3.47 USD/shares -3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $893,369,000 USD 105%
Assets, Current $1,126,587,000 USD 71%
Property, Plant and Equipment, Net $24,029,000 USD 345%
Operating Lease, Right-of-Use Asset $20,742,000 USD -16%
Assets $1,186,958,000 USD 72%
Accounts Payable, Current $8,082,000 USD 23%
Employee-related Liabilities, Current $17,097,000 USD 31%
Liabilities, Current $50,625,000 USD 20%
Operating Lease, Liability, Noncurrent $15,283,000 USD -20%
Liabilities $214,829,000 USD 250%
Accumulated Other Comprehensive Income (Loss), Net of Tax $475,000 USD 7817%
Retained Earnings (Accumulated Deficit) $1,396,142,000 USD -47%
Stockholders' Equity Attributable to Parent $972,129,000 USD 54%
Liabilities and Equity $1,186,958,000 USD 72%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $105,893,000 USD -35%
Net Cash Provided by (Used in) Financing Activities $141,241,000 USD -65%
Net Cash Provided by (Used in) Investing Activities $1,458,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 164,950,540 shares 61%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $36,806,000 USD -75%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $895,740,000 USD 105%
Deferred Tax Assets, Valuation Allowance $419,243,000 USD 45%
Deferred Tax Assets, Gross $424,843,000 USD 44%
Operating Lease, Liability $20,278,000 USD -15%
Payments to Acquire Property, Plant, and Equipment $981,000 USD 414%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $445,745,000 USD -40%
Lessee, Operating Lease, Liability, to be Paid $22,877,000 USD -18%
Property, Plant and Equipment, Gross $32,750,000 USD 169%
Operating Lease, Liability, Current $4,995,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,284,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $5,130,000 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.058 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,599,000 USD -33%
Lessee, Operating Lease, Liability, to be Paid, Year Three $5,442,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $267,026,000 USD 210%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,606,000 USD 3%
Additional Paid in Capital $2,367,780,000 USD 50%
Depreciation, Depletion and Amortization $2,049,000 USD 22%
Deferred Tax Assets, Net of Valuation Allowance $5,600,000 USD -16%
Share-based Payment Arrangement, Expense $45,851,000 USD -0.03%
Interest Expense $2,904,000 USD
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%